Specialty Pharmacy

Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.

The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.

Study finds the COVID-19 pandemic has drastically improved the quality and convenience of virtual cancer care.

According to research conducted at Rush University Medical Center, opioid use may increase patients’ risk of developing pancreatic cancer.

The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.

The FDA has granted fast track designations to cavrotolimod (AST-008) for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma.

The Association of Community Cancer Centers offers virtual learning series.

Pvsripo is a novel immunotherapy that activates patients’ innate and adaptive immune system to enable anti-tumor response and establish immunologic memory to prevent the recurrence of cancer.

A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.

Pralatrexate, a lymphoma drug, outperformed remdesivir in treating COVID-19 in a lab experiment.

According to the study authors, this could lead to finding the exact molecular trigger and gives hope for developing a targeted PsA treatment in the future.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.

FDA approves request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate that appears to directly elicit tumor cell death and prompt the immune system to eliminate tumors.

Pharmacists must juggle the delicate balance of integrating clinical services into traditional dispensing environments, while being forced into performance metrics set forth by corporate entities.

Pharmacy Times®, the leading multimedia resource for pharmacy professionals, adds the Association of Community Cancer Centers to its Strategic Alliance Partnership program.

Socioeconomic and racial health disparities contribute to worse cancer and COVID-19 outcomes.

According to the study authors, previous small studies suggested that women taking statins may have less heart muscle damage from these types of chemotherapy, yet the exact mechanisms of how statins protect against the cardiac cell damage remains unknown.

The FDA has granted a breakthrough therapy designation to tiragolumab for use in combination with atezolizumab (Tecentriq) in the frontline treatment of patients with metastatic non­–small cell lung cancer.

This study points to the potential for using CAR T-cell therapy effectively against solid tumors, as well, according to the authors.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.

The FDA has granted a fast track designation to an investigational antibody-drug conjugate for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer.

Reports indicate a mortality rate of up to 28% among solid organ transplant patients hospitalized with coronavirus disease 2019.

The biologics license application lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA.

Consumption of sugary drinks regularly may be a major contributory factor to the epidemic of cancer, according to a study published by the British Medical Journal.

The research team designed TETi76 to replicate and amplify the effects of a natural molecule called 2-hydroxyglutarate (2HG), which inhibits the enzymatic activity of TET genes.

Randall A. Oyer, MD, discusses rising cancer mortality during the coronavirus disease 2019 (COVID-19) pandemic and what that means for cancer care.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the disease impact on the gynecologic system and how often patients become infertile due to this impact.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, details the treatment options available for patients with congenital plasminogen deficiency.